HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US

The company will focus on two phase 3 clinical trials in the US and Europe to get fast approval for RGN-259

HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
Jae-Young Han 1
2023-04-13 17:25:36 jyhan@hankyung.com
Bio & Pharma

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment for neurotrophic keratopathy, which is currently in development through its US subsidiary Regentry in Phase 3 clinical trials in the United States.

The company is developing RGN-259 as an eye-drop treatment for both dry eye syndrome and neurotrophic keratopathy.

The Phase 3 trial in the US involves administering RGN-259 to 70 patients for four weeks.

The company plans to conduct clinical trials of the same substance in Europe as well in order to shorten the approval period.

Write to Jae-Young Han at jyhan@hankyung.com
#HLB Therapeutics #RGN-259 #Regentry #Phase 3 clinical trials #neurotrophic keratopathy

HLB Cell develops organoid biomaterial based on human normal cells

HLB Cell develops organoid biomaterial based on human normal cells

HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeeded in producing an extracellular matrix rich in human basement membrane components through normal cell culture for the first time in the world.&nbs

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effective and safe in first phase 3 clinical trials (SEER-1).The research report, published by the International Journal of Molecular Sciences on Dec. 29,

HLB Therapeutics signs contract for COVID vaccine distribution rights

HLB Therapeutics signs contract for COVID vaccine distribution rights

Moderna vaccine at Incheon Int'l Airport (Courtesy of Yonhap) South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention Agency after being selected as a contractor to build and operate a storage and distri

Retail investors test Celltrion, HLB shares as Korea’s GameStop

Retail investors test Celltrion, HLB shares as Korea’s GameStop

Celltrion Inc. and HLB Inc., two leading South Korean biopharmaceutical shares, shot up on Monday as the main bourse’s key index climbed back above the psychologically important 3,000 points.The usual suspect behind Celltrion’s rally was its announcement during the day that its bio
(* comment hide *}